CA2696021C - Macrocyclic compounds useful as inhibitors of kinases and hsp90 - Google Patents

Macrocyclic compounds useful as inhibitors of kinases and hsp90 Download PDF

Info

Publication number
CA2696021C
CA2696021C CA2696021A CA2696021A CA2696021C CA 2696021 C CA2696021 C CA 2696021C CA 2696021 A CA2696021 A CA 2696021A CA 2696021 A CA2696021 A CA 2696021A CA 2696021 C CA2696021 C CA 2696021C
Authority
CA
Canada
Prior art keywords
compound
equiv
disease
eomo
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2696021A
Other languages
English (en)
French (fr)
Other versions
CA2696021A1 (en
Inventor
Nicolas Winssinger
Sofia Barluenga
Martin Karplus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Strasbourg filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2696021A1 publication Critical patent/CA2696021A1/en
Application granted granted Critical
Publication of CA2696021C publication Critical patent/CA2696021C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
CA2696021A 2006-08-11 2007-08-10 Macrocyclic compounds useful as inhibitors of kinases and hsp90 Active CA2696021C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83715406P 2006-08-11 2006-08-11
US60/837,154 2006-08-11
US85873106P 2006-11-13 2006-11-13
US60/858,731 2006-11-13
PCT/US2007/017754 WO2008021213A1 (en) 2006-08-11 2007-08-10 Macrocyclic compounds useful as inhibitors of kinases and hsp90

Publications (2)

Publication Number Publication Date
CA2696021A1 CA2696021A1 (en) 2008-02-21
CA2696021C true CA2696021C (en) 2015-09-29

Family

ID=39082315

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2696021A Active CA2696021C (en) 2006-08-11 2007-08-10 Macrocyclic compounds useful as inhibitors of kinases and hsp90

Country Status (7)

Country Link
US (2) US8067412B2 (enExample)
EP (1) EP2136799B1 (enExample)
JP (1) JP5465006B2 (enExample)
CN (2) CN101588799B (enExample)
CA (1) CA2696021C (enExample)
ES (1) ES2651019T3 (enExample)
WO (1) WO2008021213A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
CN101588799B (zh) 2006-08-11 2013-09-11 斯特拉斯堡大学 用作激酶抑制剂和hsp90抑制剂的大环化合物
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
CA2708143C (en) 2007-12-07 2016-10-11 Francis G. Fang Intermediates in the synthesis of zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
KR20160017105A (ko) * 2008-01-15 2016-02-15 유니베르시떼 드 스트라스부르 치료제로서 유용한 레조르실산 락톤의 합성
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
CA2808866A1 (en) 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
AU2011319685B2 (en) * 2010-10-22 2016-02-04 Le Centre National De La Recherche Scientifique Pochoxime conjugates useful for the treatment of HSP90 related pathologies
EP2771008A4 (en) * 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
US3239346A (en) 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
FR96016E (fr) 1966-06-29 1972-05-19 Commercial Solvents Corp Composé utilisable comme supplément alimentaire pour les animaux.
US3453367A (en) 1966-06-29 1969-07-01 Commercial Solvents Corp Methods for treating inflammation with estrogenic compounds
NL131183C (enExample) 1966-12-13
US3758511A (en) 1967-01-18 1973-09-11 Merck & Co Inc Preparation of d,1-zearalenones
US3551454A (en) 1967-07-26 1970-12-29 Merck & Co Inc Preparation of optically active (-)-zearalenone and intermediates therefor
US3586701A (en) 1967-08-24 1971-06-22 Commercial Solvents Corp Norzearalane and its production
US3887583A (en) 1968-05-15 1975-06-03 Commercial Solvents Corp Products and process
US3591608A (en) 1968-11-15 1971-07-06 Ayerst Mckenna & Harrison Macrocyclic ketolactones
US3621036A (en) 1969-02-27 1971-11-16 Merck & Co Inc Derivatives of zearalane
US3860616A (en) 1969-05-01 1975-01-14 Merck & Co Inc Synthesis of d,1-zearalanol
US3704249A (en) 1969-05-01 1972-11-28 Merck & Co Inc Synthesis of the biologically active diastereoisomer of (-) zearalanol
BE757083A (fr) 1970-02-16 1971-03-16 Commercial Solvents Corp Nouveaux produits a activite antibacterienne
BE757082A (fr) 1970-02-16 1971-03-16 Commercial Solvents Corp Procede de preparation de nouveaux produits a activite antibacterienne
US3687982A (en) 1971-03-09 1972-08-29 Commercial Solvents Corp Separation of mixed diastereoisomers of zearalanol
US3810918A (en) 1972-04-25 1974-05-14 Commercial Solvent Corp Synthesis of zearalanone
US3836544A (en) 1972-04-25 1974-09-17 Commercial Solvents Corp Synthesis of zearalanes ii and related compounds and intermediates useful in the syntheses thereof
US3903115A (en) 1972-04-25 1975-09-02 Commercial Solvents Corp Synthesis of zearalanes II and related compounds and intermediates useful in the syntheses thereof
US3852307A (en) 1972-04-25 1974-12-03 Commercial Solvents Corp Synthesis of zearalanone and related compounds
US3901922A (en) 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanone and related compounds and intermediates useful in their synthesis
US3957825A (en) 1972-04-25 1976-05-18 Commercial Solvents Corporation Process for synthesizing zearalanone and related compounds
US3901921A (en) 1972-04-25 1975-08-26 Commercial Solvents Corp Synthesis of zearalanes and related compounds and intermediates useful in the syntheses thereof
US3925423A (en) 1974-01-22 1975-12-09 Commercial Solvents Corp Resorcyclic acid lactones and their production
US3965275A (en) 1974-02-11 1976-06-22 Commercial Solvents Corporation Composition and method
US3954805A (en) 1974-06-06 1976-05-04 Commercial Solvents Corporation Process for preparing zearalene type compounds
US4035504A (en) 1975-05-12 1977-07-12 Imc Chemical Group, Inc. Method for treating cholesterolemia by administering resorcylic acid lactone derivatives
US4088658A (en) 1976-11-04 1978-05-09 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4042602A (en) 1976-11-04 1977-08-16 Imc Chemical Group, Inc. Synthesis of dideoxyzearalane and related compounds
US4228079A (en) 1978-10-30 1980-10-14 W. R. Grace & Co. Dialkoxy monorden derivatives
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
EP0248916A1 (en) 1986-06-05 1987-12-16 C.R.C. Compagnia di Ricerca Chimica S.p.A. Method for separation of 3S,7R-3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one from its 3S,7S-diastereomer
US4751239A (en) 1987-06-29 1988-06-14 International Minerals & Chemical Corp. 6' Carbonate esters of zearalanol and its derivatives
US4778821A (en) 1987-07-15 1988-10-18 International Minerals & Chemical Corp. Method for controlling helmintic parasites
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
US4902711A (en) 1988-01-19 1990-02-20 Pitman-Moore, Inc. 6' Carbamate esters of zearalanol and its derivatives
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
IE911915A1 (en) 1990-06-06 1991-12-18 Sankyo Co Radicicol derivatives, their preparation and their¹anti-tumor activity
JPH06279279A (ja) 1993-03-26 1994-10-04 Tsumura & Co 血管新生阻害剤
JPH06298764A (ja) 1993-04-15 1994-10-25 Kyowa Hakko Kogyo Co Ltd 免疫抑制剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
JP3938936B2 (ja) * 1995-04-26 2007-06-27 協和醗酵工業株式会社 ラディシコール誘導体
US5710174A (en) 1995-06-07 1998-01-20 Zymo Genetics, Inc. Factor XIIIA inhibitor
JPH09202781A (ja) 1996-01-25 1997-08-05 Sankyo Co Ltd ラディシコール誘導体
DE69728974T2 (de) 1996-10-25 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Radicicolderivate
JPH10265381A (ja) 1997-03-24 1998-10-06 Sankyo Co Ltd 血管再狭窄予防剤
AU3534499A (en) 1998-04-24 1999-11-16 Kyowa Hakko Kogyo Co. Ltd. Radicicol derivatives
US6635671B1 (en) 1998-12-24 2003-10-21 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
JP2000236894A (ja) 1999-02-19 2000-09-05 Kyowa Hakko Kogyo Co Ltd ラディシコールの製造方法
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
KR20030046397A (ko) 2000-07-28 2003-06-12 슬로안-케테링인스티튜트퍼캔서리서치 세포증식성 질환 및 바이러스 감염의 치료 방법
US6734209B2 (en) 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
AU2001278152C1 (en) 2000-08-04 2009-02-05 Board Of Regents, The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
DK1309569T3 (da) 2000-08-18 2011-01-24 Millennium Pharm Inc N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamidderivater som PDGFRs-inhibitorer
DE60120427D1 (de) * 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
EP1335920B1 (en) 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Compositions containing purine derivatives for binding to hsp90
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
US20030211469A1 (en) 2001-07-16 2003-11-13 Lloyd Waxman Inhibiting hepatitis c virus processing and replication
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2003113183A (ja) 2001-10-05 2003-04-18 Kyowa Hakko Kogyo Co Ltd リウマチ治療剤
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
AU2002364566B2 (en) 2001-12-12 2009-03-26 Conforma Therapeutics Corporation Assays and implements for determining and modulating HSP90 binding activity
GB0202871D0 (en) 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
JP4575667B2 (ja) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬として有用な大環状化合物
EP1498104A4 (en) 2002-04-17 2006-05-03 Taisho Pharmaceutical Co Ltd TONIC PRODUCT FOR HAIR GROWTH
WO2004024142A1 (ja) * 2002-08-29 2004-03-25 Kyowa Hakko Kogyo Co., Ltd. Ｈｓｐ９０ファミリー蛋白質阻害剤
US20060251574A1 (en) 2002-12-12 2006-11-09 Adeela Kamal Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1666064A4 (en) 2003-08-22 2008-12-17 Kyowa Hakko Kogyo Kk MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION
WO2005061481A1 (en) 2003-12-19 2005-07-07 Sloan-Kettering Institute For Cancer Research Novel ma crocycles and uses thereof
WO2005105077A1 (en) 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
WO2006119456A2 (en) 2005-05-04 2006-11-09 University Of Vermont And State Agricultural College Methods and compositions for treating toxoplasma
CN101588799B (zh) 2006-08-11 2013-09-11 斯特拉斯堡大学 用作激酶抑制剂和hsp90抑制剂的大环化合物

Also Published As

Publication number Publication date
CN101588799A (zh) 2009-11-25
ES2651019T3 (es) 2018-01-23
US8067412B2 (en) 2011-11-29
WO2008021213A1 (en) 2008-02-21
CN103539769B (zh) 2016-03-16
US8450305B2 (en) 2013-05-28
CN103539769A (zh) 2014-01-29
US20120077775A1 (en) 2012-03-29
CN101588799B (zh) 2013-09-11
CA2696021A1 (en) 2008-02-21
EP2136799B1 (en) 2017-10-04
JP5465006B2 (ja) 2014-04-09
US20080146545A1 (en) 2008-06-19
JP2010501478A (ja) 2010-01-21
EP2136799A4 (en) 2010-10-27
EP2136799A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
CA2696021C (en) Macrocyclic compounds useful as inhibitors of kinases and hsp90
JP6159350B2 (ja) 治療薬として有用なレゾルシン酸ラクトンの合成
CN102015673B (zh) 用作治疗剂的大环前药化合物
US20140135290A1 (en) Macrocyclic prodrug compounds useful as therapeutics
HK1151522B (en) Macrocyclic prodrug compounds useful as therapeutics
HK1150010B (en) Synthesis of resorcylic acid lactones useful as therapeutic agents

Legal Events

Date Code Title Description
EEER Examination request